In the beginning, we give a general explanation of the NSCLC common treatments and then continue our study by focusing on the targeted therapy of NSCLC, which be discussed separately in the VEGF, KRAS, EGFR, ALK, ROS1, BRAF, RET, MET, NTRK, HER2, HER3, PI3K/AKT/mTORC, PD1, and CTLA-4 related sections. This evidence concerns the gene KRAS and non-small cell lung carcinoma.